JFG
NBIX icon

Jefferies Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Jefferies Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$329K Buy
+2,500
New +$332K ﹤0.01% 1353

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's NBIX Position: Q1 2026 in Review

Jefferies Financial Group reduced its Neurocrine Biosciences (NBIX) stake by 93% in Q1 2026, selling an estimated $5.7M and leaving 3,046 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

Jefferies Financial Group first reported a position in NBIX in Q4 2022 and has held it in 8 quarters since. The position peaked at $6.52M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Jefferies Financial Group held 3,046 shares of Neurocrine Biosciences worth $401K as of Q1 2026.
  • Jefferies Financial Group sold 42,930 Neurocrine Biosciences shares in Q1 2026, an estimated $5.7M.
  • Neurocrine Biosciences made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1299 holding.
  • Jefferies Financial Group first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 8 quarters since.
  • Jefferies Financial Group's Neurocrine Biosciences position peaked at $6.52M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.